A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes

Background: In 2015, Ikervis® became the only EMA-approved cyclosporine A (CsA) eye-drop for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. Since the 1980s, CsA has been used empirically for ocular conditions...

Descripción completa

Detalles Bibliográficos
Autor principal: Eroglu, Yasmina Iffet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560409/
https://www.ncbi.nlm.nih.gov/pubmed/28839524
http://dx.doi.org/10.1080/20016689.2017.1336043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560409/
https://www.ncbi.nlm.nih.gov/pubmed/28839524
http://dx.doi.org/10.1080/20016689.2017.1336043

Ejemplares similares